Press Releases March 27, 2026 05:35 PM

Magna Posts 2025 Annual Report

Magna International Releases 2025 Annual Report and Announces 2026 Shareholders Meeting

By Marcus Reed
Share
Twitter Reddit Facebook LinkedIn
MGA

Magna International Inc., a leading global automotive supplier, has published its 2025 Annual Report, including financial statements and management analysis. The company announced its 2026 Annual Meeting of shareholders will be held virtually on May 4, 2026. Magna's reports are accessible on their website and regulatory agencies in Canada and the U.S.

Magna Posts 2025 Annual Report
MGA
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Magna published its 2025 Annual Report inclusive of financial statements and management discussion.
  • The 2026 Annual Shareholders Meeting will be conducted virtually on May 4, 2026.
  • Magna continues to maintain a global footprint with operations spanning 28 countries, with key markets in North America, Europe, and China.

AURORA, Ontario, March 27, 2026 (GLOBE NEWSWIRE) -- Magna International Inc. (TSX: MG; NYSE: MGA) today announced that its 2025 Annual Report, including Management’s Discussion and Analysis and Audited Consolidated Financial Statements, Annual Information Form (AIF) and Form 40-F, are now available on the company’s website, www.magna.com. Magna has also filed these documents with the Canadian Securities Administrators (accessible through its website at www.sedarplus.ca) and the U.S. Securities and Exchange Commission (accessible through its website at www.sec.gov/edgar).

Please click HERE for the 2025 Annual Report.

Please click HERE for the Annual Information Form.

Our 2026 Annual Meeting of Shareholders will be held on Monday, May 4, 2026, commencing at 10:00 a.m. (Eastern Daylight Time). The meeting is being conducted as a virtual-only meeting accessible at www.virtualshareholdermeeting.com/MGA2026.

Magna will provide a paper copy of its audited financial statements as contained in our 2025 Annual Report to shareholders, free of charge, on request through our website, www.magna.com, or in writing to Magna International Inc., Attn: Corporate Secretary, 337 Magna Drive, Aurora, Ontario L4G 7K1, Canada.

INVESTOR CONTACT
Louis Tonelli, Vice President, Investor Relations
[email protected] │ 905.726.7035

MEDIA CONTACT
Tracy Fuerst, Vice President, Corporate Communications & PR
[email protected] │ 248.761.7004

ABOUT MAGNA
Magna is one of the world’s largest automotive suppliers and a trusted partner to automakers in the industry’s most critical markets—North America, Europe, and China. With a global team and footprint spanning 28 countries, we bring unmatched scale, trusted reliability, and proven execution. Backed by nearly seven decades of experience, we combine deep manufacturing expertise with innovative vehicle systems to deliver performance, safety, and quality.​

For further information about Magna (NYSE:MGA; TSX:MG), please visit www.magna.com or follow us on social.


 

 


Risks

  • Automotive industry cyclicality and dependence on automaker demand impacting Magna's revenue streams.
  • Potential geopolitical and regulatory uncertainties in key markets like North America, Europe, and China which could affect operations.
  • Market competition and technological innovation pressures within the automotive supply sector.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026